-----BEGIN PRIVACY-ENHANCED MESSAGE-----
Proc-Type: 2001,MIC-CLEAR
Originator-Name: webmaster@www.sec.gov
Originator-Key-Asymmetric:
 MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen
 TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB
MIC-Info: RSA-MD5,RSA,
 O1a2HF9mRNrKDh2fifGilhxiEEAM4MtIAE+KdqZ5a9BfOxM83FkAk9j+1nkf12SH
 bP+ts5kfVQkwPbZLsw0KYg==

<SEC-DOCUMENT>0001075880-07-000018.txt : 20070417
<SEC-HEADER>0001075880-07-000018.hdr.sgml : 20070417
<ACCEPTANCE-DATETIME>20070416200203
ACCESSION NUMBER:		0001075880-07-000018
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		2
CONFORMED PERIOD OF REPORT:	20070417
FILED AS OF DATE:		20070417
DATE AS OF CHANGE:		20070416

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			NOVOGEN LTD
		CENTRAL INDEX KEY:			0001075880
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		FISCAL YEAR END:			0630

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-29962
		FILM NUMBER:		07769312

	BUSINESS ADDRESS:	
		STREET 1:		140 WICKS RD
		STREET 2:		NORTH RYDE
		CITY:			NEW SOUTH WALES 2113
		STATE:			C3
		ZIP:			2113
		BUSINESS PHONE:		01161298780088

	MAIL ADDRESS:	
		STREET 1:		107 NORTH RYDE
		CITY:			SYDNEY
		STATE:			C3
		ZIP:			1670
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>form6k20070419.htm
<DESCRIPTION>FORM 6K 2007-04-16
<TEXT>
<html>
  <head>
    <title>
      Form 6K 2007-04-16
</title>
<!-- Licensed to: 97ut5rw-->
<!-- Document Created using EDGARizer HTML 3.0.4.0 -->
<!-- Copyright 2006 EDGARfilings, Ltd., an IEC company.-->
<!-- All rights reserved EDGARfilings.com -->
</head>
  <body bgcolor="#ffffff"><br>
    <div>
      <hr style="MARGIN-TOP: -5px; COLOR: #000000" noshade size="4">
      <hr style="MARGIN-TOP: -10px; COLOR: #000000" noshade size="1">
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 36pt; FONT-FAMILY: Times New Roman"><strong>UNITED
      STATES</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 36pt; FONT-FAMILY: Times New Roman"><strong>SECURITIES
      AND EXCHANGE COMMISSION</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 18pt; FONT-FAMILY: Times New Roman"><strong>Washington,
      D.C. 20549</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>______________________________________________</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 18pt; FONT-FAMILY: Times New Roman"><strong>Form
      6-K</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 18pt; FONT-FAMILY: Times New Roman"><strong>REPORT
      OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER
      THE</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 18pt; FONT-FAMILY: Times New Roman"><strong>SECURITIES
      EXCHANGE ACT OF 1934</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 14pt; FONT-FAMILY: Times New Roman">For
      the
      month of April, 2007</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 14pt; FONT-FAMILY: Times New Roman">Commission
      File Number </font><font style="DISPLAY: inline; FONT-SIZE: 14pt; FONT-FAMILY: Times New Roman">________________</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 36pt; FONT-FAMILY: Times New Roman"><strong>Novogen
      Limited</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 14pt; FONT-FAMILY: Times New Roman">(Translation
      of registrant&#8217;s name into English)</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 18pt; FONT-FAMILY: Times New Roman">140
      Wicks
      Road, North Ryde, NSW, Australia</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(Address
      of principal executive office)</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">___________________________________</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 14pt; FONT-FAMILY: Times New Roman">Indicate
      by check mark whether the registrant files or will file annual reports under
      cover of Form 20-F or Form 40-F. </font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 14pt; FONT-FAMILY: Times New Roman">Form
      20-F
</font><font style="DISPLAY: inline; FONT-SIZE: 14pt; FONT-FAMILY: Wingdings"><strong>x</strong></font><font style="DISPLAY: inline; FONT-SIZE: 14pt; FONT-FAMILY: Times New Roman"><strong>&#160;</strong></font><font style="DISPLAY: inline; FONT-SIZE: 14pt; FONT-FAMILY: Times New Roman">Form
      40-F
</font><font style="DISPLAY: inline; FONT-SIZE: 14pt; FONT-FAMILY: Wingdings"><strong>o</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 14pt; FONT-FAMILY: Times New Roman">Indicate
      by check mark if the registrant is submitting the Form 6-K in paper as permitted
      by Regulation S-T Rule 101(b)(l):</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 14pt; FONT-FAMILY: Times New Roman">Note:
      Regulation S-T Rule 101 (b)( I) only permits the submission in paper of a Form
      6-K if submitted solely to provide an attached annual report to security
      holders.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 14pt; FONT-FAMILY: Times New Roman">Indicate
      by check mark if the registrant is submitting the Form 6-K in paper as permitted
      by Regulation S-T Rule lO1(b)(7):</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 14pt; FONT-FAMILY: Times New Roman">Note:
      Regulation S-T Rule l01(b)(7) only permits the submission in paper of a Form
      6-K
      if submitted to furnish a report or other document that the registrant foreign
      private issuer must furnish and make public under the laws of the jurisdiction
      in which the registrant is incorporated, domiciled or legally organized (the
      registrant&#8217;s &#8220;home country&#8221;), or under the rules of the home country exchange on
      which the registrant&#8217;s securities are traded, as long as the report or other
      document is not a press release, is not required to be and has not been
      distributed to the registrant&#8217;s security holders, and, if discussing a material
      event, has already been the subject of a Form 6-K submission or other Commission
      filing on EDGAR.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 14pt; FONT-FAMILY: Times New Roman">Indicate
      by check mark whether the registrant by furnishing the information contained
      in
      this Form is also thereby furnishing the information to the Commission pursuant
      to Rule l2g3-2(b) under the Securities Exchange Act of 1934. Yes </font><font style="DISPLAY: inline; FONT-SIZE: 14pt; FONT-FAMILY: Wingdings"><strong>o</strong></font><font style="DISPLAY: inline; FONT-SIZE: 14pt; FONT-FAMILY: Times New Roman"><strong>&#160;</strong></font><font style="DISPLAY: inline; FONT-SIZE: 14pt; FONT-FAMILY: Times New Roman">No
      </font><font style="DISPLAY: inline; FONT-SIZE: 14pt; FONT-FAMILY: Wingdings"><strong>x</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 14pt; FONT-FAMILY: Times New Roman">If
&#8220;Yes&#8221;
      is marked, indicate below the file number assigned to the registrant in
      connection with Rule 12g3-2(b):</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 14pt; FONT-FAMILY: Times New Roman"><strong>SIGNATURES</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 14pt; FONT-FAMILY: Times New Roman"><strong>Pursuant
      to the requirements of the Securities Exchange Act of 1934, the registrant
      has
      duly caused this report to be signed on its behalf </strong></font><font style="DISPLAY: inline; FONT-SIZE: 14pt; FONT-FAMILY: Times New Roman">by
      the
      undersigned, thereunto duly authorized.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 14pt; FONT-FAMILY: Times New Roman"><strong>Novogen
      Limited</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 14pt; FONT-FAMILY: Times New Roman">(Registrant)</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 14pt; FONT-FAMILY: Times New Roman"><strong>/s/
      Ron Erratt</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 14pt; FONT-FAMILY: Times New Roman">Ronald
      Lea Erratt</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 14pt; FONT-FAMILY: Times New Roman">Company
      Secretary</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 14pt; FONT-FAMILY: Times New Roman"><strong>Date
      16 April, 2007</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div>
      <hr style="MARGIN-TOP: -5px; COLOR: #000000" noshade size="1">
      <hr style="MARGIN-TOP: -13px; COLOR: #000000" noshade size="4">
    </div><br>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
    <div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
      <div id="FTR">
        <div id="GLFTR" style="WIDTH: 100%" align="left">&#160;</div>
      </div>
      <div id="PN" style="PAGE-BREAK-AFTER: always">
        <div style="WIDTH: 100%; TEXT-ALIGN: center">&#160;</div>
        <div style="WIDTH: 100%; TEXT-ALIGN: center">
          <hr style="COLOR: black" noshade size="2">
        </div>
      </div>
      <div id="HDR">
        <div id="GLHDR" style="WIDTH: 100%" align="right">&#160;</div>
      </div>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="right">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 14pt; FONT-FAMILY: Times New Roman"><img src="novogen2.jpg" alt=""></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 14pt; FONT-FAMILY: Times New Roman"><strong>ASX
      &amp; MEDIA RELEASE</strong></font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 27pt">&#160;</font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 27pt">&#160;</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 14pt; FONT-FAMILY: Times New Roman"><strong>16
      APRIL, 2007</strong></font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 27pt">&#160;</font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 27pt">&#160;</font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 27pt">&#160;</font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 27pt">&#160;</font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 27pt">&#160;</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 14pt; FONT-FAMILY: Times New Roman"><strong>NOVOGEN
      LIMITED'S US PATENT ISSUED FOR PHENOXODIOL</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 14pt; FONT-FAMILY: Times New Roman">Novogen
      Limited (Nasdaq: NVGN; ASX:NRT) advises that it has been granted patent claims
      in the United States to pharmaceutical compositions of the anti-cancer drug
      candidate phenoxodiol. Acceptance of the patent by the US Patent and Trademark
      Office was received in December 2006, and this patent has now been granted
      with
      an issue date of April 2007.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 14pt; FONT-FAMILY: Times New Roman">The
      granted claims in the US are to pharmaceutical compositions and unit dose forms
      of various substituted isoflav-3-enes (including phenoxodiol). The period of
      exclusivity is anticipated to be at least until 2017, with up to a five year
      extension to 2022 potentially available under US legislation known as the
      Hatch-Waxman Act. </font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 14pt; FONT-FAMILY: Times New Roman">This
      patent now adds significantly to the Novogen intellectual property portfolio
      surrounding phenoxodiol, which already includes granted protection for certain
      pharmaceutical uses including the treatment of cancer, and pending patent
      applications for manufacturing processes and modes of action. This portfolio
      includes granted protection in the US, UK, Australia, Singapore, New Zealand,
      Hong Kong, Czech Republic, and Turkey and pending applications elsewhere around
      the world. </font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 14pt; FONT-FAMILY: Times New Roman">The
      rights to develop and commercialise phenoxodiol have been licensed to Novogen&#8217;s
      US oncology subsidiary Marshall Edwards, Inc. (Nasdaq: MSHL). Phenoxodiol is
      now
      in a multi-national phase III clinical trial in combination with carboplatin
      as
      a chemotherapy resensitiser for advanced ovarian cancer, which is known as
      the
      'Ovature' trial. </font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 14pt; FONT-FAMILY: Times New Roman">JPMorgan
      Securities of New York is coordinating the Marshall Edwards, Inc. international
      out licensing and commercialisation strategies for phenoxodiol. </font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 14pt; FONT-FAMILY: Times New Roman"><strong>About
      phenoxodiol</strong></font><font style="DISPLAY: inline; FONT-SIZE: 14pt; FONT-FAMILY: Times New Roman">&#160;</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 14pt; FONT-FAMILY: Times New Roman">Phenoxodiol
      is an investigational drug and, as such, is not commercially available.
      Phenoxodiol is a novel-acting drug that inhibits key pro-survival signalling
      pathways operating via sphingosine-1-phosphate and Akt. Inhibition of these
      pathways leads to prevention of phosphorylation of key anti-apoptotic proteins
      such as XIAP. Loss of activity of these proteins restores the ability of
      chemoresistant tumour cells to undergo apoptosis in response to chemotherapy.
      The putative molecular target for phenoxodiol is a tumour-specific protein,
      accounting for the highly selective nature of the drug. </font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 14pt; FONT-FAMILY: Times New Roman"><strong>About
      Novogen </strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 14pt; FONT-FAMILY: Times New Roman">Novogen
      is an Australian based biotechnology company in the business of research and
      development of drugs derived from its phenolic technology platform. The Company
      manages its research and development programs utilising the expertise and
      clinical research capabilities of universities and hospitals in Australia,
      USA
      and Europe. Novogen&#8217;s drug program is researching and developing compounds for
      the treatment of cancer, cardiovascular disease and inflammatory disease.
</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 14pt; FONT-FAMILY: Times New Roman"><strong>About
      Marshall Edwards Inc.</strong></font><font style="DISPLAY: inline; FONT-SIZE: 14pt; FONT-FAMILY: Times New Roman">&#160;</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 14pt; FONT-FAMILY: Times New Roman">Marshall
      Edwards, Inc. (Nasdaq : MSHL) has licensed rights from Novogen Limited (Nasdaq
      :
      NVGN) to bring three oncology drugs - phenoxodiol, NV-196 and NV-143 - to market
      globally. Marshall Edwards, Inc. is majority owned by Novogen, an Australian
      biotechnology company that is specializing in the development of therapeutics
      based on a flavonoid technology platform. Novogen, based in Sydney, Australia,
      is developing a range of therapeutics across the fields of oncology,
      cardiovascular disease and inflammatory diseases. More information on
      phenoxodiol and on the Novogen group of companies can be found at </font><font style="DISPLAY: inline; FONT-SIZE: 14pt; FONT-FAMILY: Times New Roman"><u>www.marshalledwardsinc.com</u></font><font style="DISPLAY: inline; FONT-SIZE: 14pt; FONT-FAMILY: Times New Roman">
      and
</font><font style="DISPLAY: inline; FONT-SIZE: 14pt; FONT-FAMILY: Times New Roman"><u>www.novogen.com</u></font><font style="DISPLAY: inline; FONT-SIZE: 14pt; FONT-FAMILY: Times New Roman">.
      </font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><em>Under
      U.S. law, a new drug cannot be marketed until it has been investigated in
      clinical trials and approved by the FDA as being safe and effective for the
      intended use. Statements included in this press release that are not historical
      in nature are "forward-looking statements" within the meaning of the "safe
      harbor" provisions of the Private Securities Litigation Reform Act of 1995.
      You
      should be aware that our actual results could differ materially from those
      contained in the forward-looking statements, which are based on management's
      current expectations and are subject to a number of risks and uncertainties,
      including, but not limited to, our failure to successfully commercialize our
      product candidates; costs and delays in the development and/or FDA approval,
      or
      the failure to obtain such approval, of our product candidates; uncertainties
      in
      clinical trial results; our inability to maintain or enter into, and the risks
      resulting from our dependence upon, collaboration or contractual arrangements
      necessary for the development, manufacture, commercialization, marketing, sales
      and distribution of any products; competitive factors; our inability to protect
      our patents or proprietary rights and obtain necessary rights to third party
      patents and intellectual property to operate our business; our inability to
      operate our business without infringing the patents and proprietary rights
      of
      others; general economic conditions; the failure of any products to gain market
      acceptance; our inability to obtain any additional required financing;
      technological changes; government regulation; changes in industry practice;
      and
      one-time events. We do not intend to update any of these factors or to publicly
      announce the results of any revisions to these forward-looking
      statements.</em></font></div>
  </body>
</html>



</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>novogen2.jpg
<DESCRIPTION>NOVOGEN HEADER
<TEXT>
begin 644 novogen2.jpg
M_]C_X``02D9)1@`!`0$`8`!@``#_X0!P17AI9@``24DJ``@````$`!H!!0`!
M````/@```!L!!0`!````1@```"@!`P`!`````@#`P#$!`@`9````3@``````
M``!@`````0```&`````!````141'05)I>F5R(%-O9G1W87)E(%-U:71E`(#_
MVP!#``(!`0$!`0(!`0$"`@("`@0#`@("`@4$!`,$!@4&!@8%!@8&!PD(!@<)
M!P8&"`L("0H*"@H*!@@+#`L*#`D*"@K_VP!#`0("`@("`@4#`P4*!P8'"@H*
M"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*
M"@K_P``1"`"G`<(#`2(``A$!`Q$!_\0`'P```04!`0$!`0$```````````$"
M`P0%!@<("0H+_\0`M1```@$#`P($`P4%!`0```%]`0(#``01!1(A,4$&$U%A
M!R)Q%#*!D:$((T*QP152T?`D,V)R@@D*%A<8&1HE)B<H*2HT-38W.#DZ0T1%
M1D=(24I35%565UA96F-D969G:&EJ<W1U=G=X>7J#A(6&AXB)BI*3E)66EYB9
MFJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&Q\C)RM+3U-76U]C9VN'BX^3EYN?H
MZ>KQ\O/T]?;W^/GZ_\0`'P$``P$!`0$!`0$!`0````````$"`P0%!@<("0H+
M_\0`M1$``@$"!`0#!`<%!`0``0)W``$"`Q$$!2$Q!A)!40=A<1,B,H$(%$*1
MH;'!"2,S4O`58G+1"A8D-.$E\1<8&1HF)R@I*C4V-S@Y.D-$149'2$E*4U15
M5E=865IC9&5F9VAI:G-T=79W>'EZ@H.$A8:'B(F*DI.4E9:7F)F:HJ.DI::G
MJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4U=;7V-G:XN/DY>;GZ.GJ\O/T]?;W
M^/GZ_]H`#`,!``(1`Q$`/P#]_****`"BBB@`HHHH`****`"BBB@`HHHH`***
M*`"N)TG7(#\<-=\*JP5H?"VEW*1XYP]SJ2D_^0Q7;5\K^(OC3;^!?^"L>A_"
M_5+E$C\<_!QTTR)I<;[NQO[B9E''S,8I9&`XP(R><\7%-[')BJT*+@Y/=I'U
M);'Y-O<`9J2JUA,T^Y]@"E5VD-G/7^F/SJS4O<Z[W"BBBD`4444`%%%%`!11
M10`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%
M`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`
M%%%%`!7X]_\`!?\`^*7BK]FW]NCX#?M&>"9BM]X?TVZGC/.V18KF,R1G'9D=
MD)Z[6/K7["=:_';_`(.DO#@C/PB\8",X@.J6*MV^80N!_P"0Z[\M498M1:NF
M?+<82E2R:56'Q1::/U'_`&7?CGX)_:2^"/A_XV_#W4%N-*\0:7!=0@'YH6*#
M=$X[.C94CU!KT+(/0U_/E_P12_X*C2_L8_$5_@K\6=5_XMWXIOX\74B?\@6\
M9BHF&#S&V[Y^"?D4]`:_?7P_KNEZ_I$6M:)?Q75K<PK);7$+;DE1AD,I'!!'
M(]0:C'86>&JOL;\.9[A\YP*DI>_%*Z-BBCI17&?1!1110`4444`%%%%`!111
M0`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`
M!1110`4444`%%%%`!1110`449'K10`4444`%%%%`!1110`4444`%%&0>AHH`
M***,@]#0`5^87_!SIX*DU?\`9,\&^-4CR-'\;+"YV<J)[>4`Y],Q'\Q7Z>U\
M9?\`!<_X5M\0O^"9?Q"2RM3+<Z$+#6+968D@07D+3'/M#YWYUTX.3AB8R1XG
M$5%XC):\%ORM_<?SGF3R6,!7((PQSU!SD?C7Z8?\$8?^"QU_\#-7L?V6OVH/
M$C/X-N1Y/A?Q%?SD_P!CS,V5MI6.3Y#$L`3]S`'0"OS,G1@0Q;)R<^XZ`_F#
M3S=)*@5U'`(!QR*^NQ%&&)ARR/P'*<VQ.2XR-:CTW1_7AIFNV6K6D=[8S1RQ
M2*"DB2`JP(R"#T(]".#5Q6W?_KK\5?\`@B)_P5VO/`VN:9^QY^T[XHEET6[G
M\CP7XEOI<_8VV#9:2N?^69;Y4)R59U0GFOVCL)4E3S$;(95*\Y&.>]?(XO#3
MPM7E9_0&29SA\YP:K4WKU78L4445S'LA1110`4449%`!111D>M`!1110`449
M'3-%`!1110`4444`%%&1ZT4`%%&1ZT4`%%!('4T4`%%%%`!11D>M&1ZB@`HH
MR#T-%`!1110`449`ZFC(]:`"BBB@`HHR!U-%`!1110!CCQ;X:;Y5UVR)/11,
M.:N:;JFFZ@C/97<4R@`DPG<._I]#7\L3Z[J[J4;5;O!ZXN#7Z`_\$-/V_KOX
M3_$^3]F+XG:T&T3Q=>)_PCEU=S$+9:FQ*K""<X28E5`SPX`&=_'@8?/J5>NJ
M;5KGZGGWA;CLEP,\13J^TY5>R70_:=65E#J>#TI:J6U])+"K_9^&4L.<=^E6
MQTKWS\KOJ(V`<FLW5_$FB:4WDZEJD,#XR$=\''KBK\_0#-?C7_P<<ZAJ%C^T
M=X)6QNWB\WPPY8HQ'/G,,\$9/3KGI7+C,3]4H>T/>X:R&?$F<1P*ER\UW?TW
M/V#TG7M(UR#S])U&*YB5RK/"^X*<9P<=#R./>M.,`$L.X%?G1_P;C7&H7W[+
M?C*>_P!1FGQ\0IE3SY2Y5?L%EP"Q)QG<?^!5^BJ-MXQTHPM=8BBJO<Y,ZRQY
M+FM3!.7-R.UR2H97$:;V'%.,[`X*C\Z^>?VYO^"BWP6_8B^'O_"0^-;A;_7+
MQ&_L7PW:W2"XO&4X8Y_Y9HI/+GC/`R2`=ZE2%&'/-V1R87"8G'5XT</'FD]%
M8^@%O;91F255STR<9KA_'/[3W[/GP[NFL?&WQF\-:7,K;6AO=7AC=3Z$,V17
MX2?M3?\`!5W]K?\`:GU>YAN/']YX7\.3RNB:%X;O)+>,Q$`[99E(>7`X.Y@A
MSRO-<7\(OV#?VS_VA[=?$7P\^!GB?5+2?YEU6_A,$++TW1RW!C60<8RA8<<5
MXTLZC4J.%"#D?J.'\+7A*,:V;8J-)-7M=7/WPT+]NO\`9!\42+;Z'^T?X0F=
MVP@.N0J"?Q:O1]!\5^'O$%H-0T;7;.]MY,>5/9SB1'^A4D&OY\_%7_!)3_@H
M9X/TXZWJO[-VJW"1+ND_LV^M[F1![)'(9&^B@FO./AW\;/VGOV3/&[GP1XS\
M3>$-7MI@MUITC2P[BI.%FMY!AP/FX8'&3TS6+SNO3E:K2:1HO#++,?%O+\PC
M*72+:U/Z8O.\S)@8>N&%<E^T1\-;+XQ_`;Q=\+;JW2:/Q!X=O+`Q2?=8RPL@
MS^)%?!/_``3O_P""Z6@?%W5-/^$/[4MI9:#KEQB&R\3POLLKURV%1P?]0Y&,
M98@D'[N=H_1O[:MQ8F6T*RJ0<$-U!Z&O:PF,I5Z<:E+8_,L^X?S+**D\)C86
M=FK]'\S^1SQ#HE[X:U2X\-ZG$\=UI]P]M=1.FTI(F%88/3IT[<BJ-?4W_!9;
M]G^X_9]_X*"^/-,$&RR\2ZE)XBT\K'A2EY(TCJ.V%E\Q?H!TSBOEN-%<X9\?
MA7Z)AJT:E&+1_)V94)8;'U*;5K-DUHS9WB0JP!VL.H/]?ZU^X?\`P06_X*A7
M/Q^\$_\`#)OQU\1^=XP\,V"?\(WJ=VY:76+!`5VNQ^]/$`N3U=6#=0^/PV9R
M3QQ72_!SXL^.O@?\4=!^+7PVU>2PUS0-3BN["YC;'S*P)1A_$KKE&7H58@\&
MN?'8*.*@V]SU.&\\KY+CE):P>Z/ZU;<QM$/+'&.YJQTKQ#]@W]K'PO\`MA_L
MR^&?CGX7DA"ZI:E=2MUE):TNT++-$01G(<9&>JD&O;Z^-J1=.HX/H?T1AJ]/
M$X>-6GM)7#I4<L\,0WN3QZ*33I&((`&<@]Z\+_X*%?M'/^RU^RIXO^+<-TD-
MY;Z>;?1RSX)NY@8HL<'.'=6_X":RJ35.#D]D=>&H5,5B84::O*3LCUV?QOX3
MMLF?7[50OWBTX`'XUJ6TL<R^;$<AE!!QU!K^;S]@#X.>*?VG_P!L#P;\*QJ5
M^UE/J:W>LM'=,/*LX5\V0DCH#M,?^\P'>OZ-O#\)L-/AM$B(184"!CS]T<5Q
MX+&1QD.91L?2\5\-QX9Q,*'M>>4DI/R3-(G`ZU3:YLE(,THR>AP:\,_;C_X*
M&?!?]ACP0GB+XAW`OM6O&*:-X<L9P;J]8#J!_`@/!<\9(')(!_&C]K'_`(*X
M_M>_M0W]S;R>.[GPAX>D^6+0O#-]);@(3SYLX99)3Z\JI'&RHQF98?"RY'K+
ML5P_P9FW$252FE"EUE+8_=CQW^TK\`OAI<M9>//C%X<TJ>,9>WO-7A21!_M*
M6R/RKG-!_;N_8\\3W/V30OVC_"-Q(&P476H0<_BPK\"_A/\`L,_MC?M'6R:S
M\-_@1XAUBT?F/5I[<002AN=R23LBOTY*Y[9/2NM\3_\`!)'_`(*">'].:[N_
MV<;^^B@^\FG75K=2(3SS&DA)_`5P+.,8UI1=C["7AYD%"?LZV90Y_)Z']">D
M>*?#'B.QAU/1==L[RVN!F"XM;A7CD&,Y5E.#P.U7[9PY8AP1Q@"OYF/!'QF_
M:?\`V0OB`1X5\9^*O!NMVI'VO3[F66`L.0!-;O\`+(/<@CWS7Z<?\$Y_^"[6
MB_$K5+3X0?M96EEHFM7+Q0Z?XGB<QVEW(3M`F5LB%B=H#`["6QA>,].%SBA7
MER5%RR\SR,]\-\TRG#_6<+.->EU<=S]-:*K6.I1W\"W,&UT<91D?(;Z&K->P
M?G*=PH/2FRR&-=P7/':O(_VK?VT_@M^QU\/I_'WQDUU+1`=MC81.&N+V0CA(
MDZL>Y/11R3BIG.-.#G)V2-L/1K8JNJ-&+E)[)'J)O[2*,RRW2A=P'([GM7/>
M,_C5\)/A^BOXZ^)&B:0-F\#4M1CA.WUPY%?B)^UI_P`%LOVJ_P!H?49M$^%N
MMMX!\/898;?1ILWLBJ?O2W"\J2.=J;0,9SC->">"/V:_VO?VEKEM7\&?##QS
MXQ:X</)JK6MS<PR,Q)W//)\N3@\E@#CJ<5X<\ZO*V'AS(_3<O\,JSP_M<UQ4
M*'EU/Z"!^V_^R(SB)?VCO!Q+=`-<@Y_\>KJ_#?QX^"OC"X2S\*_%3PYJ4TA(
M2*QU>&5C@9/"L3T!K\"5_P""2G_!1<+]I'[+NJ$@<$ZGIY8?@9\UQ'C;]D']
MLCX+1MJ'C/X&^-M$MHL-)?V^DW7D]0`3+""@YP`<]3VZTEG&)7QTF=R\-\AK
MZ8?,X.79L_I174+25]B,C8&>/>K","N0N`.U?@+_`,$__P!O[]N?P3\;O"WP
MB^'_`(\OO$]KK>MV^F_\(]XDGENHXU:55;:[,9(BBLS,0Q`"\C@5^^6DO<2:
M7"]V`)3'^\"]-W?&:]3"8N&*H\]K-;GP/$W#&)X:Q4:56HIJ6JL^A:+*$!)^
ME9USXBT"TN7MKO5[:.0`$QRR@'!Z'!_G5R0%T4`]".W7FOQ)_P"#@/5=4L?V
MS-,M(-1G6-?"%NP6.8J-WFR@G'3)P/RIXO%+"4'5>I'#&0?ZQYI'!<_)=7N?
MM./%?AGOKEE_W_6D_P"$K\,_]!NR_P"_ZU_-G\+/V:?VL_C=X=;QA\(O@]XQ
M\1:5'</`^H:5932Q>:H4L@9006&\<5T__#`?_!0+_HV?XA?^"BX_^)KRXYS5
MDM*3/NZOAIE="JZ<\S@FM&K_`/!/Z)O^$J\-$9_MNRP.O[]:=!XK\.7;^3!K
M$#L.BI(">W8?6OYUF_8#_P""@GWA^S-\1"!UQI%QC_T&O>O^"97['G[9/P\_
M;6\&^-/B-\"/&.EZ'933&^U#5M)F6"%3#(`&8C'WMO7-:4<TQ%2I:5)I'FYE
MP+EF7X">(IYA";CT35_S/W$R#5>_U*PTU!-?7*1+@D,YP..M3K]T9]*^0/\`
M@N4UU!_P3Y\4WMI)L>*YL_G`Y`-Q&"`1R,C(KUJLU3I.?8^"P&$>.QE/#IV<
MFE]Y]4?\)AX8G?9'KEH2#C!F`_K5U+N$LH2,$,,A@*_EB_M[65/_`"&+PD<9
M%R1_*OVH_P""(W[?,O[1?PE'P2^)&L+/XO\`"=N%6:>8M)?V(&V.;)Y9@0RM
MUZHW\6!Y66YQ3QU5P:MV\S[SBOPWQ_#F7K%PJ\ZZKL??T9&XCOBG5#;.9)'.
MWY>-K`]:FKV3\XM8K7#0Q@%SP.Y%9C>-?"B7<EJWB"V$L;E)(_,&4(SD$=NA
M_*M&]ADE@<1S;&*D*VW.#ZU_-[_P4`US6X?VV/BO!)K5Z\<?CS50(S>.$"":
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MF+]L;]GR'3/%.LC_`(37PK$EGXAB9UW7*\B*[7CE77&>.'1ATKZ]R!P37\U/
M[&'[4?CW]AS]I&P^*.GVER#9SO9>)]%W8-Q;9(FB*G!5E*@C/0Q\]17]%_PQ
M^)W@OXO^!M*^(G@+5XK_`$K5K1+BSN8B</&PR#SR/0@\@@@\BOHLGQGMZ/LJ
MC]];GXGQ[PS#(LS=?#?[O5O*#[=U^)TD^"`:_&;_`(.0`#^TCX&SV\*N?_([
M5^RSLI..^17XT_\`!R!_R<EX'_[%1O\`TH:GG;_X3I'1X6K_`(S*C_AE^1]!
M_P#!M[Q^RGXR/_519O\`T@LZ_10D;]N>HK\Z?^#;X_\`&*WC+_LH<W_I#9U^
MBY568ENP%:91_N<3Q..K?ZUXJ_\`,_R/,OVJ?VC?"?[*/P5USXT^-ILVFDVQ
M:*V#A6N9CQ'"F?XG;`%?SK?'[XY_$K]JKXM:A\6/B+>2ZAK.K7(BM+=%+_9T
MW8CMXE/.Q"<`#DD^M?HC_P`''GQ[N+K7?!7[-NE7[+;P!M:U:->DCMNA@!^G
M[T_C7A__``0V_95L_P!H']J0?$;Q3IHNM#\!P+>2PS1Y6:^<LL(;_=(:;']\
M`]J\;-:\L=C5A(GZ3P'@L#PUPM5SW$1_>-/EOWZ?>?5__!+C_@C3X+\`>%M-
M^/'[4OABVU;Q1>QQW6E>'KZ/?;Z4A&Y#*A!$LX!SD\+G`&<U^C5AHNEZ3IZ6
M.G6,<$,8Q'%$H"J.P`'0"K5G%Y>?H/ZU/7TF&PU/"TE"*V/R'-\YS#/,7*OB
MJC=^E]$5?L=M(C12*'5AAE89!KP[]M']@;]G_P#;)\"OX?\`B+X+M4U6&-O[
M'\0V<"I>6,N`%9)!@D#C*'*D#ITKWNHKDD8(]#6E2C2K0<9JZ9P83$5\!5C4
MH2LT[H_FD_:Z_93^(G['OQGU'X4?$"RWO$OF:5J,$96+4;7(VS*3W7."ISM8
M$=1FOT\_X(8_\%"M4^-OA"?]F'XOZY)>>(_#UK]HT/4+B7,E_8C"&-L\M)&<
M$GNLBYY!SZ-_P6\_90L?V@/V4;[Q[I&CH_B'P0&U*QN`GS/;`#SX21R5*@-]
M8Q7X[_L=?'#4?V=OVF_!?QAT^[=/[(UJ$705MHEM7)BEC8#@YC=QGWKY50>4
M9@HI^Y(_?/;4?$#@R<JZ3Q%'JM]%I]Y^C/\`P<N_LIMXZ^"GA?\`:=\*Z-YN
MH>#;J33];:,'+V-R4\MFYY,<JA5]YSGH*_$ZXMM@RIQ[BOZO?B?\/_!O[1/P
M>U;X;^*[-;S1?%.C2VMW$QX:*6,C<O<,-P*GL0I[5_,1^UG^S;XT_9+_`&@_
M$O[/OCM#]JT"^*V]TR[5O+9@'AG7/9XV4^QW`X*D#]1RG$J4?9G\.>(635<-
MC5C8K=^]IM;3]#S.GQJQ0NAP58$$=B#D?RIE/B(`;-?0-I:GYC=K8_2O_@W)
M_;%G^$_QVU#]E?QEJ[#1?',+7.A!Y.+?4X@H*Y;H)8L@8_B11C+5^ZV1ZBOY
M'_A/\2?$7P;^)>@_%7PG<B'5/#NJ6]]9,6/^LBE$@''\)`9&'<-7]5'P1^)>
MA_&KX6^'?BSX78-IWB+1X-0L3NY\N6)9`#[@LP_"OE<WH*-7VBZG[7P!FCKX
M&6'F[RCJO\CLYY-K`>H.*_)7_@XT_:,GO-<\*?LPZ/J),,.-;UBWC8?,Q62.
M%6[\`R-CU(/4`C]6?$6HV6BZ0^JZF^R&VB>220C[@522WM@`U_-_^V/\8M7_
M`&N/VO?%?Q%TN.:ZEUSQ"+31+>-<EK='6"VC0>K(J'\SV-?%9[B)0PGLX;R/
MZ-\+\I6/SUXNJOW=&/,[[7/T`_X-SOV:([;P[XJ_:GUK3MHN[HZ)X?:099HD
MVR7#@^F]E3ZQFOT*_:C^/_@W]F'X'^(?C9XWO#%9:)I\DZQJ?GGDP=D2`]79
ML*!ZD5E?L<_`2V_9B_9T\*?!BQ@7&DZ:D=[)&`!+<L`TLGXN6-?G[_P<<_M`
MWT$/@?\`9KT*Y:..83ZUK<8;J1B.U!_V0WG,1URJUHY/+,J4E\21P\D^->.)
M4U\,I_=%:_H?G9^TM^T/\1_VJ/B_JOQ:^)NIF[O=2FVP6@;=#:0#`2"-<8"J
M!CIR2Q.2Q)_3O_@EK_P1I\)>!]+T[XZ_M8^%8=4\0W'[_2O#%ZI>WTU"ORM-
M&1B2;D\-E4(!QN'R_*?_``1"_92TW]H7]K3_`(3;Q1IJ3:#X%MUU*9)4W":]
M:0"V7GC@JSG'=/<5^\R(%4+C@5PY1@8XC_:JVLGL?9^)'$U3+9+(\LER4XI<
MS6FI0T[1=)TFT2RT_3X;:%%`CAAC"JH`P``.@]JG^S6I<.5!(Z$CI5FBOI.5
M7/Q'WGJW=G@W[8G["G[/?[87@.X\.?$WP5`=0\EAI>OVZ[;NS<\@H_IVVG*X
M)XK\&OVQ?V1_B-^QK\8KKX6^/87DA7<^AZLL;)'J%J#A9ESRK<_,O5#QG(S7
M]+K`E?EZ]J^-/^"V/[)%E^T?^R5J/C#3],637?`5M<ZSIT@`WO"J`W,0]=T2
M%@.[Q)UQ7E9IE]'$4_:)6DNQ^@\"<7X[(\>L-4GS4*CLT];7/'?^"%7_``4*
MUSXN^')OV4OBSX@:ZUOP[8^=X;O+E_WEY8J?FBSU=XLK[[&7.2*_2ZOYBOV5
MOC;J?[.?[0/A7XT:5=R1_P!C:Q#<7JQC)D@9]L\8_P!Z-B![*1W%?TS:=JUK
MJ=C#>VTRR+/$'C93D,",Y%3D^,GB*3IR=W$OQ(R&EDV;^VH1M2JJZ]>OYG*?
MM%?&7PQ^S_\`"C6/B]XTU-;72]"T^6ZNF+`%]@R$7/5F.%`[E@*_G9_:_P#V
ML_B9^V=\9[WXL?$"_F,<K^5HFEJ2(K*U!'EHBCN>&+'))8\XK]$_^#C?]HRZ
MTWPGX+_9OT"[=1J\\VK:['&Y4F&(I'`GIAI&E8CK^Y'J,_-/_!#+]DBS_:%_
M:G_X6%XLTM)=#\`01Z@T<JEQ/J#2+Y"\\;5VM(>^8X_>N',\15Q6+6%CMU/K
M.",!A.'.&ZG$.)2<]>2_X?>SZC_X)??\$8/!_A71M-^-O[7OA*'5M=N5$^F>
M%-07?!IH*Y5ID/#S<G@_*N!P6!V_I9HOAK0?#UBFF:'I,%G;QJ!'!;1A%08Z
M`#@#V%:84*,`=*6O>PV$HX6GRTT?DV<YWF6>XR6(Q<VV^G1%86D(X$>WUP<5
M#<Z+I=]9FUO+*.2,C:5<=JOT5NDK:GDJ\97B[,\BM?V+/V8=-^-MC^T+I/P?
MTFR\7V$$T,&KV<9B=Q(NTEU0A78#(#,"1N;!&37J<6(8C'M(VKG![5:P/2BB
M,(QO9;FE>M6Q$E*I)MI65W<KD_)GW7^8K\0?^#@\Y_;4TW_L3[;_`-&RU^WK
M_P"L;ZK_`#K\0?\`@X.Y_;4TT?\`4G6W_HV:O(SM7P27H?H7A9*,.+8.7\K/
ML;_@WE@CD_8?U$L@&/'M\=WOY%M_@*^^?*@_NC\J^!_^#>9T3]AK427`_P"*
M]OB1G_IWMZ^^MT`&1M_*N_`7EA(W['RO%C3XFQ7+I[[_`#&BWB8@@X`ZC'6F
M-:V[,=L*G=][MG_.*E6XB0X+*`>].9]V'09!Z&NKJ?/KW%?N2#I7R%_P7+D"
M_P#!.KQA'GEKBR_]*8Z^O:^/_P#@N?\`\H[/%W_7Q9?^E,=<^+_W:?H>]PY%
M3S[#1?\`/'\S\:OV&_V=+?\`:H_:#@^!]Q-Y<NL:+JAL9W)"PW,5C-+"_P`I
M!.)%3(.1ANE9_P`&OBC\7/V)OVD[3QCIMI/I/B#PIJK0:GI]PV`Z_=FMI`.-
MK(2.F1P1@@$>T_\`!#[!_P""DG@T#_GQU/\`](I:^E?^"]G[!,TT0_;-^'NB
M;!"D5MXTM[8`;UW;(KX@=QOV.?[NTX`0FOD<-AJE3`QK4='%L_H',\_I4>+9
MY1CG>A6BK7Z/5'Z1?LN_'_P9^TQ\'='^,?@6_$NGZQ813+&S#S+=R/GAD'\+
MHV58=B*]%!!&0:_#;_@B-^WJ/V>_B_\`\,\^/]4">$O&MU''8FY;"Z?J!)"@
M?W5DW%6ST(7.,&OVZL9;<VH:$;E;)#8ZGO7U.`Q4<70YENC\)XLR&IP[FLJ#
M^!N\7W3+$_$1^AK^:_\`X*$\?MO_`!='_4^:O_Z.>OZ4)_\`4GZ5_-A_P4)_
MY/@^+G_8^ZO_`.CGKS,^_AP]5^9]MX0ZYMB%_P!.S]-OV9/^3;?A[_V(^D_^
MD<5%2?LQ?\FU_#S_`+$;2?\`TCBHKK6QY567[V7JS\>O!0_XK/2!_P!12W_]
M&+7]07A>W^T^#;!&;@V,088Z@H,C\J_E^\#_`/(ZZ/\`]A6W_P#1JU_4+X*.
M?"M@A_Y\XL?]\"O.X<;E2FV?2^,S_?X677E9^.__``7:_8*7X1_$`?M5?#C3
M2-"\2W*KXF@MHPJ65^1M\\@=$E4-N_V\G^+C6_X(/_\`!0!_`WB\?L@?$[55
M_L[5YWG\)W%U/_J+DJ2]JA(QL;864<89B.=W'ZJ_&WX*>`OCU\.]6^%GQ&TI
M;W3=7LGMKB%C_"V""/<$`@]OQ-?SM?M2?L\_$O\`8<_:1U#X<ZS<7$&H:#?)
M>:'K$49C%S#NW074?<#Y<''\:N.F*>84IY=CEBX+W>I'">-P_&/#TLBQ;_?1
M5X-]?^&T/Z4+>=;D>8%&.""#U'-?C?\`\'('_)R7@8YZ^%'_`/2AJ^^?^"6/
M[;6G?MH?L\P:WJM_"/%.@+%8^*;-6`9)PI"2[>H215WCW+>E?`O_``<A'/[2
M'@7:?^97;_T>U=>;5*=?*G.&J9XWAU@L3EW'D<-65I04T_N/H/\`X-OE_P",
M5?&9_P"JB3#_`,D;.OT5D&3G/45^=?\`P;?_`/)JOC/_`+*+-_Z06=?HJW/Z
M?SK;*E_L,3YGCG7BG%_XOT/P/_X+J>)+K6_^"BOBO3)KG>NDZ;I5G&@;.P&R
M6<`^G,\A_$5]M_\`!N5X,M-._9/\4^+XPBW6J>/+B">0)R\,-K;&,$YZ@RR'
M_@5?%_\`P7C\*W/A_P#X*&ZWK.`!K>A:==H0@Y"VYMN?7F(5]@?\&W/Q#L]5
M_9\\:_#1[M/M6D>,#?>6#UAN;:)5/YP/^=>5A(0_MR4GN?I/$,:L_"O#>S>B
M<;GZ2VRE4&6[8Z5+3(?Z"GU]2?AK=V%,FC\SOC@T^HYG*E0.]%KBD[*YC^,?
M"FF>*_#&H^'=802VE]8RV]S$PR'C=&1@?JK$?C7\N.JZ<NF:K/IK2^8L%R\3
M-C&X*Y4GVX%?U"?$_P`;:9\//`>M^-M;G"6>D:9/>7+9'"11%R/TK^7>ZFN]
M7U9[J67#W,I;9@<LS$G]2:^8XE2_=/JG_D?MG@^I^SQDG\-E]_O']*_[%>MW
M?C']DKX;>+=3E$EQJO@'2+J=RO)D>RB=B?7):ODC_@NO_P`$UY_VL?A3%\=?
MA+HAN/'WA"V;%K;Q_/JMB`6>`=S(IPR=>K#C.:^QOV2_"DO@7]FCP!X)G4*V
MC^#-,LBH[>5:QQ_^RUW\EK#.I2;O^E?586K.DHS3ULC\-XAP%#-'B*$]G)_F
M?R%FQDC9XIB5DC8K)&1RC`X(/I4()0D$5^KO_!;G_@C[=^&+_4/VROV8?#$S
M:9(GF>-O#.GP;FM\')O85'.W!'F)CY=I88`(K\IK@JP5U7&[)QR>.,<D?_JK
M[3"XE8J-T?S=G.38K)L6Z51:=!/.!P#&/SK^@?\`X-WOC?+\5?\`@GS8^$[^
M^\^_\#>([S1959OF6#"7$!QV&R?8/^N9^@_GT'45^K/_``;`_%N;2OBI\3O@
MQ/>A%U32+35;:`GEG@D>-L#UVS+D]^/05R9O24L-=;H]W@+%?5<\2Z23/OG_
M`(+*_M%K^S[^Q)XC73K_`,C5_%D1T#2V1L.IN5*2LN.XBWX/8D5^7/\`P1,_
M9X'QS_;4TC6-8T83:+X&M3K=Y(02AF4K';H?]K>V[_=1J])_X."_VBY?B%^T
M7HGP)TS5!)9>"[*2:]1)1M-Y<E2RMC^Y"JX/4;LC!YKZU_X(*?LZ?\*G_9*_
MX6QK>G^3JGCR[-T"W#)9PLT4(/\`OX>0?[+BOS*<5CLTBEM`_M^A_P`8KX<R
MJ;5<4[>?+V^X^\)8R5(#``K\HQT-?@W_`,%U==N=8_;_`-7MKB=F%CH5C!&A
M/"C:S\?BQK]YI&`5]WW0.N.E?A/_`,%Z_"]WH?[>=WK,BC[/J_ARRN+9MN,A
M0T;?7E?UK?/_`/<3QO"F4%Q4HRW<;'UW_P`&YO@2RL_V;?%OCI#B?4_%I@D)
M&?DAACVC_P`B/7Z2D'&`<5^8_P#P;C?$JUO/@KXW^%TETAN-.\11WL4.>?+G
MA"Y_.%C^%?IQD=,UU94_]@@?/<;PJ4^*\5">ZD%%%%>@?*A6%\1]*M=<\':E
MH]ZH:*ZL)H9`1D%60J>._!-;M<S\7O%&F^"_AYK/BO5[A(K73=(NKNX>1L!8
MXXB[$^P`J*G\-FM!2=>'+O=?F?S!^--&M/#GC+5_#UB28;'5;FWC+=2$E90?
MTK^D']BC7KOQ?^R9\.O$=Y<%WN?!VG.[GJQ^S1J23[E2WX^U?S>>+=9C\1^*
M]3\0HH47^H37(4'IYCL_'YU_2=^R9X3N_`/[,?@'P;?0>5/IWA'3X)XQGB18
M%##\Z^:R&*6+J-'[9XM17]CX!3^)I?\`I*O^A^.O_!>[7KW4OV^+O1IY-T.F
M>&;&*W![!O,<_JU?87_!N7X5T^Q_9@\6>++?B[U+Q<8)FV_P0PQ[1_Y$:OD_
M_@X%\'W6B_MQP>+&C80:]X1LIH21P?++QM^H'YU])_\`!M[\3;/4OA/XZ^$L
MMTGVC2]:BU&*(?>V31A2?SB`J,-_R/))FF>P=7PIP]6EM[M_Z]3].Z***^K/
MPH*8TI`!"]:?6;XCOY=-T&YOH)-KPPED8C(!QZ>E*^HXQ<I**W;L:._CGTIO
MFC&<5^&]Y_P7D_;[MO&KZ5_:?A3RDU1K<J/#9;:GFE.<2Y!Q@Y/KTK]L?!&M
M3^(O!^FZU>,#-=6,<LQ48&\J"<#L,YKFPN+IXIRY>A[N=\.9IP_&G+&0LJBN
MC1?[S'W7^=?B%_P<'C'[:FFG_J3K;_T;+7[>OU?ZK_.OQ"_X.$/^3U-,_P"Q
M.MO_`$;+7GYW=X'3^MCZ7PO:7%M/TZ'`?L3?\%:OB]^P]\)9OA)X#^&OA[5K
M2;69M1:ZU2:X$@>1(T*XC<#`$?Z^W/L7_$1O^TW_`-$4\&_]_P"\_P#CM=A_
MP1R_X)U?LC_M7?LM7GQ$^-_PT.K:S#XLNK-;H:K=0_N4B@95VQ2*O!=CG&>>
MM?7'_#D7_@G-_P!$+;_P?W__`,>KEP^'S=T(^SJ)+S1]=GN=>']#.*\,5@Y2
MJ*3N[O\`S/A4_P#!QI^TRQWM\$O!IV*2/W]YP?\`O[7ZG_L;_&[7/VAOV9?!
MWQL\2:7;65[XBT6*]NK2T9C'"SY.%+$DCZUXQ+_P1&_X)S@9'P/9?7_B?W_(
M]/\`75](_"KX7>#O@KX"TKX6_#S118:!H=DMMIUGYSR>5$O1=SDLV/4DFO4P
M5',(/_:)J2\C\^XHS3A;&481RO#NF[Z[_JV=9UKX^_X+G_\`*.SQ</\`IXLO
M_2F.OL$8QQ7Q]_P7/_Y1V^+O^OBR_P#2F.NG%?[M/T9Y?#/_`"4&%_QQ_,_,
M/_@A\<?\%)O!I_Z<=3_](I:_=SXA>$/#WCKPAJ7@_P`3Z5%>6&IV3VMW;2Q[
MEE1QM*D'C!!Q7X1_\$/S_P`;)?!O'_+CJ?\`Z12U^^KQQ[?GR?>O*X?2E@&G
MW9]EXK2G#BE2@[-1C^;/YR?^"@G[(OB3]BG]HJ]\!"*Y.@W<C7_A34V./.MM
MQ'WO^>L>5!P<@D-WQ7ZN_P#!''_@H(W[4_P+C^'?C>]CD\;^$+9(-2)?#7MO
MNVQW2J>3P55CS\V#GY@*[[_@J?\`L0Z3^V;^SG>:+H]G"/%6@1S:AX5N)(P2
M;E5!\@GJ$EVA#[[3VK\0/V9?VB/B3^Q%^T99?$W1(+JWOM%O7L];TE_D:>`-
MB:W;CDDJ`!TW(#U`KAGSY/B[Q^"70^DH>R\1.%72;_VJ@M/-?\,?TM2MFW+>
MU?S8_P#!0H#_`(;A^+H'3_A/M7Q_W^>OZ&_@I\9O"'QZ^&>E?$_P)J\=YI>K
M6B3VLJ,#\K#H<=&!R"/:OYY/^"A*[?VX_B\GIX^U@#_O\]=6>ZX>G+S7YGE^
M$U*I0SO%TZFDHTV?IQ^S&^/V;/AZ,?\`,CZ3_P"D<5%-_9D_Y-M^'O\`V(^D
M_P#I'%17<HJQY%5+VLO5GX_>"_\`D<=(_P"PK;_^C5K^HGP)_P`BII_'_+G%
M_P"@"OY=_!`#>,](4G'_`!-+?_T8M?U$>`]P\*V".,,+*+(_X`*\SAQKV<T?
M2>,;7M\(KZJ+-BOA_P#X++_L#7/[5/P0E^(W@/2U;QGX0M6FTX``&]MLAI;8
MXYY&YE_VA[U]P54O;6+[*[7$F4"?/NZ8KW\10AB:+ISV9^1Y9F>*RC'T\5AW
M:47^'4_G-_X)Y?M@^(OV)/VC]-^(-PUU_8EW*EAXPTT-S-;,Q5F"GK+$VYN>
M?W;`<G%?1/\`P<#>*_#/CCXQ_#GQIX2U6*]T[4O!1NK.Y@Y22)I&*M^(_6LS
M_@MG^P._[.'QA'Q\^'^F`^%/&MU+)=)''B+3M3#>8X(_A23<SKZE67C.:^._
M'/Q7\4^//!GA3P/K\I>#P=:7%II+L^YEMY9_/6(^H1BX'L0.W/Q>)K5L)2J8
M.2]/,_I+*</@^(,VPG$."TDERU%W6S;^9^M__!M]S^RMXR'_`%4.;_TALZ_1
M<G#X'<5^=/\`P;?+G]E3QF<]/B'/_P"D%G7Z+JIDRP.*^HRI..#C<_!^.+3X
MJQ37\Y^7W_!QG^SS?:YX6\)_M)Z!9/(=$D;2=;*1[MEO,1)%(>^!)'L^LJ5\
M<?\`!(3]KS3?V3OVM;"X\87GV7P[XJC.F:S(6.V-W.Z"7GIME)5C_=D)[5^[
MOQA^"_@[XW^`M9^''CZR2[TK6[![2\MW0?<88W`]F4_,#V(![5_.[^V[^Q7\
M1_V)?C%=_#KQE8RW&ESS/-X=UEHCY&HVW(['@CD.F<\\''(\O-J53"8J.,I*
M]MS]'\/,?A.(,CJ<.8N:BW?E;ZW_`,M#^D/0K^SU*V%W83+)"Z*T;IC#*<D$
M8]1S^-7J_''_`();?\%KX_@KX=L?V?\`]J-Y[K0K6-(-"\5KOEDLHE)`CN1\
MS,B@J!(/NA<$=#7ZN_#KXZ_#'XL>&[?Q9\.O&VDZS87*[H[K3KY94(R1U7Z=
M#R*]G"8ZCBZ2DI*Y^89_PSF?#V-G0K0;BG92MHUT9V-07LD*C9*"=RG:`.OM
M56]\1V>FVWVS4)8HH@I:1WD`"@=R:^._V[_^"RG[._[,FB7/ASX?:U8^,/&C
M1R1VVDV%T&@M9,?*UQ,,H@!'*@ECC&!G-;U<11HQYIR2L>;@,KQ^:5U1PU-R
MD^R.`_X+S_M@:+\)O@$/V?/"FKHOBCQF5AO(T8%K32URTC^Q=PB#ZD_PU^97
M_!/+]GK4OVFOVP/!?PRM[-Y+,:HE_K+A,K':6^)I-W8!L*GUD'K7"?%KXL_%
MC]ISXM7GQ$\?7MWK?B;Q%>(#%%$S._\`#$D4?)`12451R!@X;J?V@_X(Z_\`
M!.S4OV/_`(;S>/OBC91)XW\2QYO+<*"-,ML*4M5()&X-N9R..5'\()^7C[7.
M,SYK>Y$_<\4\'X<\&RPBDI8FK&[?6[W7R/M70K(V$36Z*!$BJL:J>@`Q^%7R
M,C%16\?EDC=V'%2U]=9+1'\^)R:O+=Z_>4M2M(=1L)+&XA62.9-LD<B@@@]0
M0>V*_%C_`(+/?\$6[[X57&I?M:?LJ^'"^@SO+=^+_#%JNY],8G<]W;+SF(Y8
MM&,[>"HP3C]L3$>S8_"JNIZ9;ZE$;2]1)(G0JZ.F0P/4$'MCC\:Z,+BJF$G=
M;'BYSDF$SG#\E5>\MF?R(2)%<J&0`#`/#<8_PK[`_P""'_QNT;X'?MZV'B77
MKQ8["]\&ZW'<R,,!1#9RWI'/3(M%_/'6O:O^"YO_``25L?V>?$%S^UA^SKHF
MSP?J=V#XJT6TC"C1+B0?\?$>,%8)&!##D(\@Z*>/SC\(:A>:=K=G=6EQ)`Q9
MX6DC?:2DB%&!/8%6(/L37T&(Q'M<MG..ME=GY+DN2U,MXSPN$KNT95(QOY-G
MTE96_C3]N_\`;.5Y3++JGQ'\<;CA>(89YMQ8CLD<9P?]F,BOZ-/A1X)T/X:_
M#G1O`&@6?V:QT;38K2TA'\,<:[%_,`'\:_(C_@WA_9I;QU\;?$O[1FK6F;/P
MA9QV6EN\>0UY<AG?'^Y&.1V\X<\5^R=O:J8E\N8D;<`XZBOSS(Z-J,JLOM-_
MF?V#XFYFJF94\MI.\*$$OG9?H3SH9K9HU&2PQ_\`7K\R?^#BW]G#4O$OPW\(
M_M(:!IK22>&9)=.UUD3</LLS*T3MZ!)L\]O-R>`:_3I5V@#/2N6^,GPN\+?&
M+X<ZO\-?&NFK>:7K.G36E[`ZY#1NN#^/<'L17I8RA'$X>5-]3XOAW-)Y)F]'
M&+[+U^>C_,_!#_@E!^UQ:_L@?M:Z=KOBO5?L_AKQ+!_8WB#<^$CC=PT<[9Z;
M)$3GLK2Y^\*_H,M-3L]0B2YLYDEC<`JZ'((_K7\X/[='[%WQ'_8<^,EU\/\`
MQ7833:%<R[_#>MF/]UJ$)`PI8YQ(HX9.ORDC.:^L/^"7/_!9]?@;IEA\"?VH
MY)[KP[:*(=+\4;C)/I\0&U8YDY:2,'`5UR5!Y!QFOG\MQLL)-X>KI;8_6^.^
M'(<2TEG>5>_=+F2W?_#'[,QGDBG5QOPV^.OPN^+N@P>*?AEXRT_6M/N(U9+J
MQNA(N",C.W.T^S8/'2NBN?$-G:PFXDFBVCJ1)G'UQTKZ=3@U=-?>?B%2C6I3
MY)P:?:S+4LJPC)%?`W_!=G]M;1/@_P#L\CX`>$];4^)/'D3V]PEL06M=.!7S
MG?\`NK)D1XZL"^,[3CK_`-NS_@L5^SK^R[X>O?#'A+6;+Q?XR:(I#HFCWH>.
M!B<!IYAE(QU.,[N.G-?B=\7?BS\5?VH/B]>?$3QM>W6LZ]K]\%@A@0M]XD1P
MPH.0H)VA1G)Y[UXF:9BJ,73IN[9^G\`\%8C'8N&8X^/)0AKKI>WJ=1^PC^SK
M>_M0?M5>%?A186,DUK/J"76L*R[MEA`ZO-G_`&2G[LGU<#N*_I2AM62%(F`^
M50/7I7PU_P`$:?\`@G7=?LI?"QOBO\2;/R?'7BF!?MUNZ9;3K,-N2U![%B%=
MQW;`(^0&ONL#!SFNC*<-[##\SWEN>7XB<1QS_.N6D[TZ7NQ_4_.S_@X0_9<U
M'XF?L^Z-\??#&E-+>^`);C^TC'G<=.G5!(YQU\MXXW!/0;O4U^;7_!-G]L:X
M_8Q_:AT[XC3S7']AZI&=-\36R*6S9O(A+JO]Y&4.,<X5@/OU_1!XW\':5XZ\
M.77A/7K:*XL+^UEM[VWFB#I-$ZE71@>"""017X%?\%.O^"</C7]B#XHW&JZ)
M87%]\/\`5+G.@:P1G[,S#=]DF;)VLOS89L!E7/7(''FN'JT:RQ-%7?4^EX`S
MG!9EE57A_'OW9?#?[S]]_"_C#PYXTT>U\0>&-7@OK.\@2:UN;:0.DD;#*L".
M"".<UJ1D;BO<=:_!7_@F]_P5P^(?[%\\'P\^(&FR>)?`A<F.S\XBYTHD'FW+
M':8^F8SCN0PY!_7W]GO_`(*&?LG?M+Z+!J_PO^+^DS7$RJ9M+O+@6UW"Q'W&
MBEVL3U&5!4XX)KT,%F%'%T[WU/B>(N#<VX?Q#4H.5-[26J_#8]PK)\5#=X>O
MO^O-_P"568->L+N`3VLRNI&>#C^E<[\1O'?AKPUX4O;W6]8M+6+[*P\VXNXT
M7D8SDL*[95*:IR=^A\Q0I598F$5%WNNA_,IJ"E?B)/[ZZ?\`T<*_IZ^&O_(@
MZ*/^H3!_Z`*_F%NW2?X@S.C9']L@E@01DR+D#Z'C/>OZ>/AHV?`.B$=]*@_]
M`%>!D/O5:K7<_7_%Z,HX?+[_`,G^1LOT;_>'\Z_$+_@X0_Y/4TS_`+$ZV_\`
M1LM?M[)PC-[K_.OQ"_X.$/\`D]33/^Q-MO\`T;+77G&F#1\WX7R4>+(-_P`K
M_(^R/^#>'_DQ_4".WCV^_P#2>WK[^K\\/^#?7Q9H&B?L4ZA9:KK%I;2MXYO7
M1+FX5"R^1;\C/;@_B#7WD/B5X([^*M-_\&$7_P`575@:E-82*;1X'%=*L^),
M4^5_$^C[F[16"WQ*\$=$\4:<3Z?VA%_\52)\1_"UQ<BTL]?TZ61L;8TOXRS'
M(X`!))YX%=:J4V[)K[SY_P!E5_E?W,WZ^/O^"Y_/_!.WQ=_U\67_`*4QU]@]
M:^0/^"YR_P#&NKQ?)_=N++C_`+>8ZRQ37U:?HSV.&G;B#"O^_'\S\PO^"'YS
M_P`%(_!G_7CJG_I%+7[]CD#-?@'_`,$/,O\`\%(O!N!TLM4'_DC,?Z5^_HZ5
MY>0*V!MYL^R\5VGQ/I_(OU*VH1228"*"`K9XZ>GZU^//_!>C]@J7P-XK'[8O
MPQT9ETO6)H[;Q;:P)\L-T5_=W(4<*'V[6/3<<GK7[&2QM)]U\<$5S7Q0^$GA
M'XP>`M4^&_CS3H[[2=8LWMM0MIDR)$92I^A`.0>Q`-=^/P<,;A94WN?(\,Y_
MB>'<WABZ>L5I*/='X_\`_!"W]O>U^#GQ%;]EKXE:OC0?$MRS^'KB5LQV=^5)
M:+)Y42X``/&Y5[L:^4/^"@LB3?MO?%N5&&'\>:N0N><>?)@X]#1^V+^S/X]_
M8G_:1U'X7ZM-<1OIUV+WP[JN=IN;3S0T,Z'^\&7!]&5A_#7GWQ3\?:G\4_'^
MM?$?6X$CO=;O)[R\6,Y!E<$L>>>3S^-?&5<555*&#J+6#1_2&3Y/A:F:U,[P
M37LZ]-W2[GZ\?LR?\FV_#W_L1])_](XJ*/V9"/\`AFWX>\_\R/I/_I'%17UT
M?A1^,U4_:R]6?G/X-_X)V_MNVOC'2KF[_9A\9QQ1:E`\KR:0RJJB126)]`.:
M_H?\"V]S:>'+2UO3^^BM8DE&,;6"@$?45KB-!SM%.'TJL#EU'`7Y-V>#Q1Q=
MF'%4Z<\5&*<>R"D=$=#&Z@J1@@TM%>@?*'FW[4W[/?@;]I;X,ZW\(/'6G^=9
M:OITT(<<O;RE?DE3/1E;!'OQT)%?S[_&#]@O]JOX1_$S6_AQ=?`SQ9JITB^:
M!-4TCP[=3VUVG598Y$C*L&4@\'@DCJ*_I1J.2VBD.6B0_45YV.RVEC6FW9H^
MTX2XVS'A1U(TES0GO%NWZ,_/_P#X-\/A[\0OAQ^S+XLTCXA>"-9T.ZG\>S2I
M:ZSIDMK(\9L;4!PLB@[21C\*_0&'[O2A((H^(T`'H!3ZZ\/15"DH)['SN<9C
M+-LRJ8MQY>=WMO8*\S_:4_9>^#?[4?P[N/AS\7_"<&I6DP!@D(*S6\@P5DCD
M7YD88ZCJ,@Y!(KTRBM)14U:6J.&C7K8:JJM*3C);-'XB_M5?\$"?V@_A;J=U
MK_[.=['XVT4R/+%9F407]NN?]7M8A)C@D;@RGCE>17RCJ?PS_:Y_9UU42S^!
M?B!X.NH),I<+97MJQVC&%E10#TZY/U-?TSE0W!%1M:PL<F%3_P`!%>-6R+#5
M'>FW'T/TO`>*.;T:"HXVE&O%=U9_?9G\S>H?$[]L3XM.?#VO>.?B1XD:7$;6
MT^IWMT7]%VL6+<]N:]-^`G_!)/\`;G^/E_`(OA!J'AFPEE'F:IXOMVM(XP3]
M\1MB60]P`B_6OZ%Q:VHY^S(/?:*>B1K]Q0/H*RAD-.3_`'TW+\#JJ^*^,I4>
M3`86%%]UJ_R1\:?L`?\`!'OX'_L<S1>/?%$B>+/&;H2VL7EOMCM&)Y\B+)"'
MI\YR_7D9Q7V(EO#$5PN-OW0O0?\`UO:K-&!Z5[5"A2PT.6FK'YGF.8XW-L4\
M1BIN4GW&1$%V.#FGT45L<*OU"FR@8IU%#U&8'C?P%X/^(_AC4/!GC?P];:GI
M>JVCVVH6-W'NCGB9<,K#W'\AZ"OYFOVY?V/_`!)^QC^UAKGP.DTZ]GTVWNQ>
M>';R2$L;G3Y6_=/N'#$$,C8_BC<=J_J$K%U/P+X8UJZ2^U?P[8W<T8`66ZM(
MW90#D`%E)`!YZUO1Q$Z4)P>JDK'D9AE%''XJAB&[3I24D_1IV_`^?_\`@DU^
MS8/V:_V+_"_AG5;'R-8UBT36-:3;AH[BX42&-CU)0;4_X#7TP%7`VC&.E-@M
MX[<;8T"C:``HP`!^E25S0A&G%1BM$>_B\35QF)E7J.[D[A45P@DPA8C@]#4M
M%4CF:NK'F'[1G[,_PA_:?^'UQ\.?C%X4M]4L)GS&\HQ+;R8XDC<?-&XSU!%?
MDU^UC_P0.^/_`,-+NY\0_LZ:I!XVT/K;Z;,1;W]NN?NX/[N<#KD,I_V:_;2D
M*J1@@8KBQ&7X3$ZSCKW/I.'^*\[X;FOJE3W>SU1_,QJGPI_;!_9TU/S+KP%X
M_P#!TT1^:[BL[RT!9>X:,!6QG@ACU]Z74?BC^V-\5T7PYJOQ!^)'B,,/EL[C
M4;Z\WCV3<W'UK^F-K:V/WX%/U44GV6S_`.?9/^^17F/(FG[M5I?UYGW7_$5%
M/WJN`IREU??\#^>#X$?\$H/VY/CYJ$$>F_!O4/#-C+(%?4?%MLUC'$IZML;;
M(YQQQ&"217ZF?\$__P#@CE\$OV2;F/Q]XVF3QAXU3:T.LWUIMCL&P0?LT9)V
M'G`<_/@<;<MG[75$7[J`?04M=F'RC"4-6KONSYK/?$#/\\INDY*%/^6)!;VU
MO;1".`;5'``Z?E4_2BBO3C%15D?#W;>HV3&0:YOXD_"GX=?%SPK=^"OB/X3L
MM8TR^C*7=E?0B1)![@]QP01R"`1S7344G%2T94)SI34H.S74_(O]KO\`X-[_
M`!#9WESXR_9#\8136S?O/^$7UN8J\1SR(K@@[AC^%P#Q]ZOA;XD_L6_MA?!&
M_E?QY\`O&&GFW8@:A#H\TUNI_O":$.I'_`OP%?TNX'3%->*)_OQ!OJ*\G$9)
MA*KYH>Z^Z/TC*/%'/\OHJCB%&M#M)'\QFD_%K]J3PY:C3='^(_CZQC0;?)AU
M>]C"^N!N&.:U;#X._MD?&B8QVOPQ^)/B8L=I^T:9?W<:G_>9"J_F/J*_I;-I
M:DY-JG_?(I5MX0<^2@^@K".223LZK:_KS/0GXI1M>E@*<9=]_P!#\&O@%_P1
M'_;M^*6L6-]XO\*67@[3@Z.USKMVIE`W9P((BYS]6'45^Z/@O2I-#\*:?HT\
M@D>SM5@=U7`8H-N0,G@XK7"*.BTM>GA,%1P<7[/=GQ'$G$^9\45XU,6U[NR6
MR*TI/EG`].OU%?D/_P`%O?V2OVD?C=^UE8>*_A+\%_$/B'38?"T%N]]I5B98
MQ(LDA*G'0C(K]@::T:-U4?E58K"PQ=+DEL<_#N>8CAS,UC:"3DE97V/YP++]
M@']O[3H?*T_]G+Q[!&7W;(=.D52V",X!QG!Q4G_#`_\`P42_Z-Z^(G_@'/\`
MXU_1T(8\8VC\J=L3^Z/RKSO[$I6MS,^YGXK9K4FYRP]-M^1_.&/V"/\`@HCG
M`_9Z^(F3_P!.<_\`C7H'[*_[%/[>/AC]H_P+X@\4?`OQY!I]EXNL)M0FN[:5
M(X84F4L[DGE0"3@^M?OYM7^Z/RH"J.0HS]*=/):,)\W,SEQ?B7F&,P\Z4L/3
M7,K:)B1;O+7=UQS7R]_P6&^%WQ`^,7[#/B;P)\,_#%]K.K74UJ;?3M.BWS2[
M9T)(!],5]1TA4-PPS7K5*<:E-P>S/@<!C*F7XVGB8*[@T]?(_$__`()"?L7_
M`+5?PH_;L\+>/_B5\"?$/A_1[.WU`W.I:E8&*./?93(J%B2"2S?I7[8CD9I!
M'&#D(/RI:PP>#I8*ER0/2XBX@Q7$F/\`K5>*3LEIY!1THHKK/!/C?_@KW^P?
MI_[7?[/5SXG\'Z,)/''A6)KWP^PCR]TN1YEJ<`L0R[MH'\6/4U^*<G[)_P"U
M(C%&_9F\?'$;Y)\(WI.-I&,"'&2<<YQS7].;*K#:PX-,-K!G/DK^0KR<;E-'
M%U543LS[SAGC[,N',#+"QCSQ>UW:WX,_//\`9Q\#>.=,_9Y\!Z;JO@S4[6ZM
M_!FEQ7-M-8S*\,BVD09&!3@@@@CVHK]#?(C_`.>:T5V+#V6YXLN(:LI-\N_G
M_P``?11174?.A1110`4'/8T44`%%%%`!1110`4'/8T44`%&`.@HHH`****`"
MBBB@`HHHH`***3<OJ*`%HI-R_P!X?G2Y![T`%%(&4C(8$#KS070=6'YT`+10
M"",@T9'7(H`,9ZT8'H*,CUI-RGHP_.@!:*3<O]X?G1N7.,B@!:*3<IZ,/SH#
MH1D,/SH`4G!Q14<LP4A4(^8'!S]/\:YKPW\7OAQXT\4:UX(\(^.],U+6/#LB
M1:[IEE>(\]@[J&02H,LA*LK#(Y!!H%=7L=311D>M(64=6'YT#%HI`RGH11N4
M]"*`%Z=336=AP!S7#?%']H/X:?"KQYX/^%_BOQ&MKKOCNZN[?PO8^6S->RVT
M0FE4$`@;4(//K796SF2!2\VXG^+UJDNIE[:/.X+5HLT4A91U8?G1O3&=PQZY
MJ346BD#*>C#\Z-Z8SN'YT`+12!E/1A^=&Y<9W#'UH`6BDWH>CC\Z-Z9QN'YT
M`+12;E_O#\ZR?'7CCPK\.O!^I>._&?B*STK2-(M7NM3U.^N%C@M84&7DD=CA
M55<DD]!0)M(UZ*R/!7BK1O&WANR\8>'-=M=1TS5+.*[TN^LYA)%<VTB[XID8
M<,KHRL".""*UBZ#JP_.@=Q#(<<+0C,V<C%<[\2/B+X:^%?@/5OB1XVU5;'1]
M#L7O-4O&1F$$$8W.Y"@DX`)Z4[X6_$+PS\5/`>D?$OP9K27^B^(=*M=2T>]4
M8%Q;3PK+%(`><,CJ>?6G;0RC6C*5D=%11UZ44C4****`"BBB@`HHHH`****`
M"BBB@`HHHH`****`"BBB@`HHHH`****``G`S7FW[5OQ9U?X$_LZ>-OC-H6E6
M]]>>&O#EUJ5M9W3E8IVAC+A&*@D`XQD#//%>DDX&:\7_`&^O#^K>,?V+?B;X
M;T31YKZ[OO!.HPVMG;1EY)I&@8*B@<DD\"KI_$<V,E4CAI<FY\P^$/\`@I[^
MUSID'PD^+/Q>_9I\.Z7\-?BWKVGZ/I-W8^())=5M9;P@6\\L6S9Y4A(88.0"
M-V#77?%?]OO]J'Q'\3?B1X:_9(^!_AC7]!^$05/%FI^)==GM)M1NQ`)Y;6QC
MAB<.Z+E29"HW+@9R,^?_`!I^$OQ,U7]@3]COP58_#_5I]2T#Q/\`#>3Q#906
M3F>PCMHK47#2#^'84;=GICWKS7Q7^SY\*O@1^V+\7YOVNOV<?B+XDT+QWXE?
M7?!?B/P1;ZA<P7,=RBF>QEBLG!617WC,@P0N00#7=%4'&[6I\Q4JYG":I\[M
MIJ?2_P`!O^"E;?&SX^^%?`UOX8M[#PIXZ^%!\9>'-7N7Q<&2.=X[JQ<#Y&,>
MS>6X)!SDCFN9_9I_X*RW?QL^%/QP^)_C+X;6NA#X6Z5-K7AZW^U28UG3"MY]
MFF(8*0TCV94@9'S+SS7FW[>/P.\5?"S]G7X)_'C]CK]G_7[6_P#"$%_IEEX-
M%FSWUGI^KZ?-`Z2H22IC+ACR=K`'M7(_M??L8?&7P!=_!WX(_![P%J.I:-\2
M?AIHOPZ^(>J65H673HK&^L9&OK@C&&9))\D]2CU2AAIZ)&=;&9I1::;?+OYW
MT_4_2+]E[XG>,/BO^SAX/^*_Q!\-6^BZQXBT"'4KW2;:1G2T,J^8L>6Y)"LH
M/;.<<8KXQUO_`(*I?M::G\"?%W[;/PQ_9J\-:A\'M"N+RWTR6[\1W$>LWPAE
M,"WX@2(QBV\TC<N\2!%=@IP,_>FG^%].LO!<'A2RC:"UM[!;6**,XV1JH50#
M[`"OR8UCXH?%+]FK_@E5\2/^">OC[]G;QB?&/A_0=7L?[:BT9O[%N-&:220Z
MC]K!V(/(\TA"=Y=57&6%<]",.=QM<]#,\3BZ$(N+LN1M^NECZQUK_@H%\?OB
M!KGP]^$/[,/PH\/ZEX\\7?#2T\:>(3XIU6>WTK0[6>.,JC/`DDDCO(S(H"X`
M`)/S'''>//\`@K)\3O#?[..E?%*R^`T5QXXM_C%%\/O&/@Q-2^2VO"MR2;6?
MCS-S11;=X"CS""/ES7AOB#X`:+X;\=?!G]ICXT?!;Q?XJ^&WB3X!Z#HU_?>#
MOM4EUH=_!;V\D3S0VDBRF-T.,@,!@]#7:?&3X"_#K6/V7?ASJ7[)_P"S1XQT
M'2K_`/:8\.:IJ5AK>FW*7URD,DBRW\D<[,\</)^9N2`#WKHY</\`RGGTL3FD
MZ#DY/9?BD>[_``B_;Q_:!\*_M(W_`.S-^VG\(/#?AW4#X%F\7Z+JOA+6IKZT
M^PPR%)HI6E1&\Y-K$X&"!P37$Z;_`,%3_P!H>/P'H_[7WB/]G[0;?X&:YXC3
M3K6ZCUV=_$$%G)<-`FH2V_E^3Y)9<E1(7`(XXKH?VH/@CXX^)_\`P4L\+R:=
MX=OQHM]\!/$&D7.MQV[-;6]S/-B-'<<*Q5V('<"OF+]E[]GK]F[P/\/-#_9E
M_:G_`&*?BE??$#2-8.FWB65GJ,VEZB/M6([])5E-NL)3:YR01M)P,XJ.3#\M
M^4*N(S2%54U)\J/JC3_V_?VF_B+^WEXR_9#^"_P"T*_TSP1?Z8^L^++_`%AH
MHH=/N+>":0A=OSW&Z8A(QD%5R3UIW[2W[87[=_[-.F^(_CSXJ_9T\$2?"OPO
MJ8BNXH?%<QUV:P,R1"]2(0^0,EP?*,@;@\=*O_L9_#7Q?X7_`&^_VF?$NI>#
MKZRTS5=5\.G1M0N[)TAO%BTN)',3GB0*?EX/!X[5^?GCOX+:YXT_9+\>>$_C
M)^R!\1?&'[2UW?7LVH^(M4TJXGMM/@%R6\^UN`P@6`0*^R*/<Q9P,<TH1IR>
MBL5B,3CZ.'2DVY-MJWE:Q]6?M%_'#]MK5O\`@I)\(=&^#&E^%IM!UCPEJ&H^
M'-'U3Q-=V]OJ-N4MVFN+Q(X2$EB#GRE4LK<[MN!GJ_"W[9WPR^!/BK]I_P"*
MWC#X+Z)H=Q\.-3L$U[4O#Z[;SQ'</9(T8E<]6W/Y:GC@@G'-87Q^U#QO\"?V
MI_V:/VC==^%?BC6?#.B?#V_T37;C0-)>]EL;NXBM1'YL48WKN.<G&/E/3!KA
M?BO^R-\9?VEO#/[9?A+P_P"!]5M+OQ;XIT?4_"'VZW-NFI&VL[>7RXV?`))C
M*'/`8@$YSB^6F]'L<].MF$-8MN5V]?-(]AT#]OS]L#X:^+/AW<_MA_L_^%O#
MOA#XI:I!I^C:EX:\0375WHEU/&9+>"_CEB107PJEHRVW=ZC%8&L?\%%/VZ_%
MOB_XRZ+\#_V9?"&I:9\&O$E[;ZKJ&N^)9H3J-I"C2Q)`JQMFX*([,"0JYC&<
ML0.8^,WQ8^(?_!1[5_@W\"?#'[-_CGPS=>'O&]AX@^(6I>)/#TEE:Z.;*-_,
MA623_6NSEU7`P0%]:](_9)^''C_0]6_;!D\0^!-4LEU_X@:C<:+Y]FRKJ,#:
M<$26`GAPQ&,CO4N-!0YFM3H]MF$L0J<)/EL^C['TS^R3\>=/_:@_9P\'_'S2
M--DLX?%&B1WOV.4@M;NV0\9(X.U@RY]N:^5[']OO]N?XJ_$3XL>`/V?_`-G/
MP??K\(/$<]GJ5_KVOSVJZC$D:R)'`J(S?:'7S#\V$&U<D;A7L7_!)+PGXM\"
M?\$[OA=X4\<^&[O2=6LO#S+?Z=?PF.:"3[1*=KJ>AP17R/\`L^_M<:Q^R_\`
MM%?M26^H?!#QGXGMM2^)4SZ)/X5T-[U9-26V5!:3;,F$LAMR&?"D`\]JQIQC
M-O0Z\;B<33I8=.5F[I_)7_0C_:F_:^UO]HCQM^QC^TO\%OAT^HZUJVN>)$L?
M#%Y>B%4U!K.*V>&63;\L:2,Q9QSM7(SFOIC]EC]L?X]_$?XL_$O]FO\`:$^#
M^C:5X\^'VE6FIP?\(OK$EQI^JV]S&S0;'E17C<L-IR,8)]#7S1\#?V4_C5\)
M=3_8KLO$/@'4GO+#Q5XLUOQ8D%NTB:+]NM%,,<[KD1\,%(_O`@?=KN/CI\./
MVF(?VM/VI_&WP-\*ZI:ZSJ7P=T*V\'ZK%$8X[J[C23='#*QP74%OH371RTI1
M47H>;AZF84Y2KR;=[-KOHCNH?VV?VTOA!\5O`NA?M<_`WP3I7AGXB^(H]#TZ
M3PCXGN+V^TJ]E1C"EPLT4<<BEL`M&Q"@D\D8J+X;?M[_`+4'QI_:H^(7P/\`
MAO\`L_:'+X;^&/BUK+Q1XIO]99-MF8FV>7%M!>Y9HY<JO[M5VG.6%?'V@_!S
MX<Z[XE^`.N?`/]C;XAVGBG0_B'HDWQ+\<^)M!NUE649,T,DLQ)FS(9&+H"BX
M&6[5]H_L$_#_`,9^'/BK^U1?Z_X5O[*+6_BO-=Z//=V;QB\A^QJN^+<!YB[@
M>1D<\43A14;HJAB\TK34+M+5_@>-M_P5[_:\T;]FNT_;;\3?LR>&D^&EIK\N
MD:Z++Q+(VHRRB_:T$UM$Z!#&"%7#DL9-W`0`U[?\$OVU/VI8?VLM'_9C_:S^
M"'AOPZWC+PU=:YX2O/#NO27GDI;X\VVN]Z*!*H.=R%E.>O6OF3Q#\$OC5)_P
M0M@^&D'PKU]_$8^)4ER=#DT]UNC&/%$DN_RR,[/+^<>JX/>OI#]H_P``?%+4
M?^"H7PG\;^"_"UW+:V'PO\3PMJWD'[);7DB)Y"2/T5F(/<<"L^6FUL5"690J
M<RE)VL_\RM\>OVT_VX?V9K6_^.7Q2_9U\#I\+=-\0I8W4-AXNN)-<%C)=BWB
MO!#Y(@((9&\OS-PY&*VOC1^W9\;?$/[0,?[)?[%?PAT;Q+XKL_#D&O\`B?5?
M%>JR66EZ59SL!#&[1(\C3N"K!`I`4Y-?GI\0/@O_`,)I^R?K?A_Q?^Q]\3O$
M?[1;:_\`:/$OBW6-'NIA8!=15EFMYW9HI(O*\M5CC#'[Y[5]9)>>/?\`@G_^
MW1XJ_:5\7?!7Q9XE\`?%;P1H5K<ZKX4TA[^?1=4TZUCMQ!+;1YD"R(I.X#`;
M@T_94K:J[*CF&-E5:;:AUT9Z?\1?VR_VI=)\>>#/V4?`7P<\&W'QFU?PK+KW
MBR'4?$-PFB:'9).\*2>=%$TTOF/'M0>6#ZXKF)/^"IWCA?@=%XKU;X1V%GXS
MT'XT6?P[\<Z%/J+O;6MS)<I%+-;RJNZ1=C;TW`9#<UY/^UKX-T3XC?M=^"OV
MY/BI^S?\1=0^&GB/X<?V+J=CIVGW<>JZ#>PWD\MO+<6MLZS;)4E(P`<9.<8Y
ML_'3X#^"6_83E^)'[&/[*WC73(=-^+>D>)]7\/:S9W":KK26<J;[E(;AFD9F
M7;C=AB%SCBFHPY5H$\5F-6O/EDTHZ)6W1]0_'#]JCXJ^`/VP/"?[*W@#P3HF
MI77BWP'J^MV-]JM])"L=Y:AO)B<(C8B=L*[CYE!!56YKY+_9,^-G[5&I_LZ_
MM0>*_P!H/P)X0\6^#=$\6^*CK=AJVOW-TWVZ*SM"=*CB:%5.GB/;A\A\R-\O
M6N]\%?%KQS^UA_P59^&'QU\-_L^^-]!\$Z+\/M9TZ+7O$^@R62W%PZ[W4H_S
M1@$JJEAASG'3GCOAA<>-O!?P0_;`_9(UWX,^,$\3>)O%'B_Q-H<Z>'9GL;RR
MGL;.*$17`'ER2NR,1$#NQ@TDE&/F35K8K%8KVG,U'7H]=$>O']O#QCX2^$WP
M`^#G[,OP#T?4_B%\4OASINKZ)X8>^-GH_AS3?L,#DRS*&811[]B!$8L(\<<9
M],U3X@_\%#=/^"MI))\#_AZ_Q*N/$OV2\@/BV=-&MM-$#-]O,WE><V'V1^4$
M#$L3C'-?+]MX"^,O[*VM_LN_MEO\(_$'B31?#_[/VE^$?'VCZ#IYEU#1]MI`
MPN/L_P!]U#/*KHHW`QCVJ[^W!\:=4_:GC^%7Q*UGX)?%1?@A;^*;Z'QWHUKH
M=S::A/(ENAM+F:WC(G:V+NPP.I!SVPO9Q;1M#&XF$)NIS<VR7D=?\1_VN/B?
M\6_V<?VD_P!F[]H;P+I'AWQ_X`\!7$VHGPWJ4MWIUY:W-DSQ3P22HDF,-R'4
M$$CBL_X6_MB_&SP%\$?V8_V1?V:OA_X8U3QEXB^`6B:W)?>-=:FLM.M+2+3;
M=`H:WBDD>1FC?Y0O``)X.:\:^$/P,U73=4_:OO?@K^REXA\"^%_%/PFAC\%Z
M'?:4T)NI1;R(2J'+*\A4-Y3-N7<<@<"N]^+F@_`1OV-_@5\,/VF_V7?B?>^)
M=$^#>A'PUXL\#^'KEK_2-22RAC-JL]N=]K.LL:MA_DYYS@UHHTO::ZHY(5<?
M*G*I=IVM_P"37_(^P_#_`,0?VMY-!L7\3?#7P=#J36<1U"&V\3RF..?8/,5"
M8P2H;(!(!Q17YL^#O"7_``<+IX1TI=$U"Y2R&FP"T36FMS>+%Y:[!.>\N,;S
M_>S14<L/([EBZ]OAD?L[1117`?6!1110`4444`%%%%`!1110`4444`%%%%`!
M1110`4444`%%%%`!UJ(V\3Q>6PRO3%%%-;">KL)]AM!\OD@9.>">M*UI:]XA
M[9S111=DN,>Q$NGV:*$6+`'0`GU)_J:!I]L/F6(##$_B22?U)HHIINXDHW>@
MZ*&*)2B,>1T-?&OQ._X)N_M5?&G1;_X6?%W_`(*+:MJOP[U6_+ZGX?M_`EO;
M:C=6ADWBS;4$N,[,[02(02N5/#&BBE&<J<W8PKT:>)BO:'UEX'\#>'_!/A33
MO!F@V*0:?I%A#96$"<"*&-%15&.@"JH_"MDVENRX>,'%%%)U)-W-H4:=-<D5
MH(MG&K;RO3/\1[T?8+,\B(`8P0!@8HHI<\F:.$)*[0"UMUX2+`[`'ITZ>G2D
M.FVC@CR5.3GG/!XZ>G04455W8AJ-]@%A;])DSSD4W^R[=/\`CVB"#'&TD>_\
M^?K112&FD[V'FR4X)B3(Z''.?6E%HI.77H<\$CVHHHV&K-;$@ACC38!@5XC^
MR_\`LC']GCQU\4?&-QX]763\2O&S^('M5TK[.-/S`D7V<-YK>;C8#OPG^Z**
M*N#:V,YT*56I'F6U[?<>S6]I:I\B*=JD8&3@8_\`U4XZ?:[1OBW8/R[F)Q^=
M%%2[MIC48I-6&#2K/<&\A<C(!QV[CW'M3O[/@C&$C"\8&***$W<;C%IZ"?9(
M3(%=<@CD9IXLHP,.I(R>K$]\T44YR:*BEM;H-DTNRE7;Y([G()&,C%$-A"A)
M,8;.?O#/?..>WM114J3>HG&$79)"C3;$'>;=0?8>Y/\`4TOV"W4Y6-0I;)&.
M"?7ZT44<S;L%HQ=TMR.32-/D7`@52>ZY!QV&1Z9X].U.&F6`D,OE`L0.I/&,
MX(]#SU'/3T%%%.[1,8Q:6FPOV"W(PB`=.A-,;1[)^MJ@YZJ,>OI]2?KS1123
M=BI*-]@@TC3H)"\=L/F.<$Y`X`X!X`X'`^O4U))I]F>L"],9'!_.BBEJM;A&
9$+6L1MI6G,Q9K-"2<DD4445%V5RQ['__V3\_
`
end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
-----END PRIVACY-ENHANCED MESSAGE-----
